Literature DB >> 9868659

Are the Duke criteria superior to the Beth Israel criteria for the diagnosis of infective endocarditis in children?

J A Stockheim1, E G Chadwick, S Kessler, M Amer, N Abdel-Haq, A S Dajani, S T Shulman.   

Abstract

Accurate diagnosis of infective endocarditis may be difficult. The Beth Israel criteria and the newer Duke criteria assign probability to the diagnosis of infective endocarditis on the basis of the presence of common features and manifestations. We reviewed 111 cases of pediatric infective endocarditis diagnosed and treated over 19 years. Each case was classified by the two criteria, and the results were compared. Of 111 cases, 73 (66%) and 18 (16%) were classified as definite by the Duke criteria and the Beth Israel criteria, respectively. No cases were rejected by the Duke criteria, while 21 (19%) of 111 were rejected by the Beth Israel criteria. In 18 pathologically proven cases, reanalysis without pathological data showed that the Duke criteria had significantly greater sensitivity (83%) than the Beth Israel criteria (67%) (P < .03). Echocardiographic evidence was required in 22 cases for definite classification by the Duke criteria; none were rejected, however, when echocardiographic findings were ignored. Our results suggest that the Duke criteria are superior to the Beth Israel criteria for the diagnosis of pediatric infective endocarditis.

Entities:  

Mesh:

Year:  1998        PMID: 9868659     DOI: 10.1086/515021

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Trials of the Use of Antimicrobial Agents in Cardiovascular Diseases.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

2.  Endocarditis in the Pediatric Population.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-12

3.  Utility of extended blood culture incubation for isolation of Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella organisms: a retrospective multicenter evaluation.

Authors:  Cathy A Petti; Hasan S Bhally; Melvin P Weinstein; Kim Joho; Teresa Wakefield; L Barth Reller; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 4.  [Diagnosis and treatment of infective endocarditis].

Authors:  D Horstkotte; C Piper
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

Review 5.  Infective endocarditis in paediatric population.

Authors:  Loay Eleyan; Ameer Ahmed Khan; Gledisa Musollari; Ashwini Suresh Chandiramani; Simran Shaikh; Ahmad Salha; Abdulla Tarmahomed; Amer Harky
Journal:  Eur J Pediatr       Date:  2021-04-14       Impact factor: 3.183

Review 6.  Infective endocarditis.

Authors:  Thomas L Holland; Larry M Baddour; Arnold S Bayer; Bruno Hoen; Jose M Miro; Vance G Fowler
Journal:  Nat Rev Dis Primers       Date:  2016-09-01       Impact factor: 52.329

Review 7.  It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations.

Authors:  Christopher D Doern; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

8.  Time-trend population analysis of the clinical and epidemiologic effect on pediatric infective endocarditis after change of antibiotic prophylaxis guidelines.

Authors:  Walter Knirsch; Stefanie Katharina Schuler; Martin Christmann; Roland Weber
Journal:  Infection       Date:  2020-04-30       Impact factor: 3.553

9.  The changing epidemiology of pediatric endocarditis at a children's hospital over seven decades.

Authors:  Lauren B Rosenthal; Kristina N Feja; Stéphanie M Levasseur; Luis R Alba; Welton Gersony; Lisa Saiman
Journal:  Pediatr Cardiol       Date:  2010-04-23       Impact factor: 1.655

10.  Fulminant Infective Endocarditis Due to Kingella Kingae and Several Complications in a 6-Year-Old Girl: A Case Report.

Authors:  Raphael Joye; Dimitri Ceroni; Maurice Beghetti; Yacine Aggoun; Tornike Sologashvili
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.